Citius Oncology (CTOR) EBITDA Margin (2025 - 2026)

Citius Oncology's (CTOR) quarterly EBITDA Margin came in at 583.54% in Q2 2026, up 66.0% quarter-over-quarter from 1716.17% in Q1 2026.

Analysis

Citius Oncology (CTOR) EBITDA Margin (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported EBITDA Margin for 2 consecutive years, with 583.54% the latest figure, recorded in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	34.95%
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	30.15%
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	32.54%
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	17.93%
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	-25,380.93%
10	Citius Oncology	101.41 Mn	101.41 Mn	1.00 Mn	-583.54%

Historic Data

Download Data